O’Melveny represented Ruichang International Holdings Limited on the transaction. Ruichang International Holdings Limited (1334.HK) announced its initial public offering and listing on the Main Board of...
You must be a Standard 1 Year member to access this content.
O’Melveny represented the sole sponsor, the coordinators and the underwriters in the transaction. Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) announced its initial public offering and listing...
You must be a Standard 1 Year member to access this content.
O’Melveny advised Acotec Scientific Holdings on the deal. Acotec Scientific Holdings, executed a voluntary partial offering for a majority stake of up to 65% by US-listed Boston...
You must be a Standard 1 Year member to access this content.
O’Melveny advised Beauty Farm. Clifford Chance has advised the joint sponsors. Shearman & Sterling advised Beijing Xinyu Meiye Holdings Limited as a selling shareholder. Beauty Farm...
You must be a Standard 1 Year member to access this content.
O’Melveny recently represented Central China Real Estate Limited and its controlling shareholder, Joy Bright Investments Limited, on the deal. Central China Real Estate Limited (CCRE) (0832.HK)...
You must be a Standard 1 Year member to access this content.
Slaughter and May, Hong Kong, acted for China International Capital Corporation Hong Kong Securities Limited, O’Melveny advised China VAST, while Latham & Watkins represented China Jinmao...
You must be a Standard 1 Year member to access this content.
O’Melveny advised Global Infrastructure Solutions Inc. (GISI) on the deal. Global Infrastructure Solutions Inc. (GISI) announced merger to bring Asia-based professional engineering consultancy J. Roger Preston Holdings...
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers LLP advised Yonghe Medical on the deal. Yonghe Medical Group Co., Ltd. (2279.HK) announced its HK$1.49 billion (approximately US$192 million) initial public offering and...
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers and Cooley LLP advised Keymed Biosciences Inc. on the deal, while Kirkland & Ellis advised the joint sponsors and underwriters. Keymed Biosciences Inc....
You must be a Standard 1 Year member to access this content.
